摘要
目的探讨强直性脊柱炎(AS)患者的疾病活动性以及药物治疗对肝功能的影响。方法分析110例AS患者的一般临床资料,并根据不同的病情活动状态(稳定期与活动期)及治疗药物分组,对各组的肝功能情况进行分析。结果本研究中,男/女发病比例为6∶1。男、女患者中发病构成比最高的年龄段均为20～40岁,其次是<20岁的青少年。活动期患者肝功能损害发生率(32.6%)显著高于稳定期患者(24.1%,P<0.05)。使用非类固醇抗炎药物(NSAIDs)治疗出现肝功能损害的有5例(8.2%)、使用柳氮磺胺吡啶(SSZ)治疗出现肝功能损害的有6例(6.3%)、使用甲氨蝶呤(MTX)治疗出现肝功能损害的有2例(4.7%),各治疗组间的差异无统计学意义(P值均>0.05)。结论活动期AS患者的肝功能异常发生率高于稳定期,应引起重视。NSAIDs、SSZ和MTX治疗对AS患者肝功能的影响无明显差异。
Objective To analyze the disease activity of patients with ankylosing spondylitis（AS） and the influence of medication on hepatic function. Methods Totally 110 patients with AS were divided into different groups according to the activity of AS and drug treatment, and then the hepatic functions were analyzed in different groups. Results The man to woman ratio in our groups was 6 ： 1. The peak time of disease onset was at the age of 20-40, follow by those younger than 20 years old. The incidence of hepatic dysfunction in the patients at active phase was significantly higher than that in those at stable phase （32.6% vs. 24.1%, P〈0.05）. The incidences of hepatic dysfunction were comparable among patients treated with nonsteroidal antiinflammatory drugs （NSAIDs, 8.2%）, Sulfasalazine （SSZ, 6.3%）, or methotrexate （MTX, 4.7%, all P〉0.05）.Conclusion Patients at active AS phase have higher incidence of hepatic dysfunction than those at stable phase AS. NSAIDs, SSZ or MTX has no obvious influence on the liver function of AS patients.
出处
《上海医学》
CAS
CSCD
北大核心
2009年第8期725-727,共3页
Shanghai Medical Journal
关键词
强直性脊柱炎
肝功能异常
活动期
Ankylosing spondylitis
Hepatic abnormality
Activation
